{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:30:50Z","timestamp":1793046650076,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T00:00:00Z","timestamp":1441152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000064","name":"National Center for Complementary and Alternative Medicine","doi-asserted-by":"publisher","award":["K23AT004433"],"award-info":[{"award-number":["K23AT004433"]}],"id":[{"id":"10.13039\/100000064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001214","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG4816-A-1"],"award-info":[{"award-number":["RG4816-A-1"]}],"id":[{"id":"10.13039\/100001214","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of General Medical Sciences of the National Institutes of Health","award":["1 U54 GM104940"],"award-info":[{"award-number":["1 U54 GM104940"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jns.2015.08.006","type":"journal-article","created":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T06:57:50Z","timestamp":1439017070000},"page":"46-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies"],"prefix":"10.1016","volume":"358","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9813-0564","authenticated-orcid":false,"given":"Jesus","family":"Lovera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deidre","family":"Devier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Kovner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-2195","authenticated-orcid":false,"given":"Tara","family":"Reza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Koop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Foundas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Bourdette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jns.2015.08.006_bb0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/ars.2008.2215","article-title":"Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons","volume":"11","author":"Schroeder","year":"2009","journal-title":"Antioxid. Redox Signal."},{"issue":"4","key":"10.1016\/j.jns.2015.08.006_bb0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nm.2324","article-title":"A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"17","author":"Nikic","year":"2011","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.jns.2015.08.006_bb0015","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.4049\/jimmunol.173.9.5794","article-title":"Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis","volume":"173","author":"Aktas","year":"2004","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.jns.2015.08.006_bb0020","doi-asserted-by":"crossref","first-page":"e25456","DOI":"10.1371\/journal.pone.0025456","article-title":"Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation","volume":"6","author":"Herges","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jns.2015.08.006_bb0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00001756-199103000-00005","article-title":"Immunohistochemical localization of N-acetylaspartate in rat brain","volume":"2","author":"Moffett","year":"1991","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/j.jns.2015.08.006_bb0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pneurobio.2006.12.003","article-title":"N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology","volume":"81","author":"Moffett","year":"2007","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.jns.2015.08.006_bb0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1471-4159.1992.tb08875.x","article-title":"Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro","volume":"59","author":"Urenjak","year":"1992","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.jns.2015.08.006_bb0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ana.10052","article-title":"N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve","volume":"51","author":"Bjartmar","year":"2002","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2015.08.006_bb0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s12031-014-0412-6","article-title":"Short-term cuprizone feeding verifies N-acetylaspartate quantification as a marker of neurodegeneration","volume":"55","author":"Krauspe","year":"2015","journal-title":"J. Mol. Neurosci."},{"issue":"45","key":"10.1016\/j.jns.2015.08.006_bb0050","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1523\/JNEUROSCI.3330-10.2010","article-title":"Assessing neuronal metabolism in vivo by modeling imaging measures","volume":"30","author":"Ciccarelli","year":"2010","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.jns.2015.08.006_bb0055","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1191\/1352458505ms1234oa","article-title":"Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"11","author":"Khan","year":"2005","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.jns.2015.08.006_bb0060","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2015.08.006_bb0065","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2015.08.006_bb0070","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2015.08.006_bb0075","first-page":"3312","article-title":"Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals","volume":"9","author":"Chow","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.jns.2015.08.006_bb0080","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1158\/1078-0432.CCR-04-2549","article-title":"Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals","volume":"11","author":"Chow","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"1-3","key":"10.1016\/j.jns.2015.08.006_bb0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.tox.2009.03.007","article-title":"Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs","volume":"260","author":"Kapetanovic","year":"2009","journal-title":"Toxicology"},{"issue":"1-2","key":"10.1016\/j.jns.2015.08.006_bb0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2006.02.008","article-title":"Determination of green tea catechins in human plasma using liquid chromatography-electrospray ionization mass spectrometry","volume":"834","author":"Masukawa","year":"2006","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"1","key":"10.1016\/j.jns.2015.08.006_bb0095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nimg.2002.1040","article-title":"Accurate, robust, and automated longitudinal and cross-sectional brain change analysis","volume":"17","author":"Smith","year":"2002","journal-title":"NeuroImage"},{"issue":"23","key":"10.1016\/j.jns.2015.08.006_bb0100","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2008.21.1284","article-title":"Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia","volume":"27","author":"Shanafelt","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jns.2015.08.006_bb0105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cncr.27719","article-title":"Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia","volume":"119","author":"Shanafelt","year":"2013","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jns.2015.08.006_bb0110","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/1940-6207.CAPR-12-0117","article-title":"Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer","volume":"5","author":"Crew","year":"2012","journal-title":"Cancer Prev. Res."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15004992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15004992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T05:56:57Z","timestamp":1537423017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X15004992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":22,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0022510X15004992"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2015.08.006","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2015.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}